
Novartis just signed a $1.6B buyout pact with a lead player in an emerging anti-inflammatory field
The executive crew at IFM has just racked up their second blockbuster-sized biotech sale in less than two years.
Not long after Bristol-Myers Squibb stepped up with $300 million in cash to ink a $2.3 billion-plus pact on the oncology applications of th… […]